By replenishing the body's master antioxidant, this therapy neutralizes oxidative stress, restores cellular function, and promotes healthier metabolic activity
In this context, numerous Chinese biopharmaceutical innovators are actively advancing their pipelines in the oral small-molecule GLP-1 space, achieving several high-profile licensing deals: In November 2023, Chengyi Bio licensed its oral small-molecule GLP-1 receptor agonist, ECC5004, to AstraZeneca with a potential deal value of up to $2.01 billion
Br J Clin Pharmacol 2025 demonstrates that co-infusing a GLP-1 agonist with glucagon produces a perfectly additive HR response (+4 bpm + +4 bpm = +7 bpm at 60 min in n=12 lean males), confirming that glucagon drives chronotropy via a parallel pathway independent of GLP-1R cross-reactivity
[1] [2] Some patients report reduced symptoms within weeks of starting treatment, whilst others may require several months of consistent supplementation before noticing significant improvement
Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing
